Does aquaporin-4-seronegative neuromyelitis optica exist?

JAMA Neurology

Volumn 71, Issue 3, 2014, Pages 271-272

  Levy, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CLINICAL FEATURE; DEMYELINATING NEUROPATHY; DISEASE SEVERITY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MEDICAL RESEARCH; MYELOOPTIC NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; SEX RATIO;

AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA;

EID: 84896795695     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.5865     Document Type: Editorial

References (12)

1. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81(14): 1197-1204.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53(5): 1107-1114.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10): 1485-1489.
4. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008; 5: 22.
5. de Seze J, Collongues N. Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard? Expert Rev Clin Immunol. 2013; 9(10): 979-986.
6. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study [published online January 13, 2013]. JAMA Neurol. doi:10.1001/jamaneurol.2013.5857.
7. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009; 66(6): 833-842.
8. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001; 7(3): 365-368.
9. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011; 69(2): 418-422.
10. Warth A, Mittelbronn M, Wolburg H. Redistribution of the water channel protein aquaporin-4 and the K+ channel protein Kir4.1 differs in low- and high-grade human brain tumors. Acta Neuropathol. 2005; 109(4): 418-426.
11. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012; 367(2): 115-123.
12. International Panel on NMO Diagnosis. Guthy-Jackson Charitable Foundation website. http://www.guthyjacksonfoundation.org/mayo-clinic-clinical-research/. Accessed November 13, 2013.